Bio-pharmaceutical company Omeros Corporation has announced pricing for a public offering of 3,478,260 shares of its common stock to be $11.5 per share.
Omeros is expected to raise gross proceeds of $40m through the offering, which will be used for general corporate purposes such as research and development (R&D) expenses for its clinical OMS721 programme, new drug applications, repayment of debt, and other capital expenditures.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cytocentrics, Inc has raised $9.18m of its planned $21.82m in venture financing by issuing equity securities to ten investors.
Specialist pharmaceutical company Recro Pharma, Inc has announced plans to raise $14.9m through an underwritten public offering of 1,986,666 shares of its common stock, priced at $7.5 per share.
Recro plansto invest the funds in ongoing Phase III pivotal clinical trial and safety studies of injectable meloxicam and for meeting other capital expenditures.
Advaxis, Inc plans to raise $30.3m through a private placement of 2,244,443 shares of its common stock, priced at $13.5 per share.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBio-pharmaceutical company Tioma Therapeutics, Inc has raised $86m in series A venture financing round.
Tioma plans to use the funds to expand its antibody portfolio and primarily its lead drug candidate, an anti-CD47 immune checkpoint inhibitor.
